Point72 Asset Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-82,993
Closed -$3.5M 1179
2017
Q4
$3.5M Buy
+82,993
New +$3.72M 0.02% 650
2017
Q2
Sell
-26,138
Closed -$3.12M 1045
2017
Q1
$3.12M Buy
26,138
+24,700
+1,718% +$2.59M 0.02% 614
2016
Q4
$143K Sell
1,438
-79,225
-98% -$8.34M ﹤0.01% 657
2016
Q3
$9.03M Buy
+80,663
New +$9.68M 0.06% 298
2015
Q4
Sell
-6,900
Closed -$713K 888
2015
Q3
$713K Buy
+6,900
New +$809K 0.01% 643

Other funds holding SIOX

Point72 Asset Management's SIOX Position: Q1 2018 in Review

Point72 Asset Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2018, closing a stake of 82,993 shares — an estimated $3.5M sold.

Point72 Asset Management first reported a position in SIOX in Q3 2015 and held it in 5 quarters. The position peaked at $9.03M in Q3 2016. 81 funds tracked by Wall St. Rank hold SIOX as of Q1 2018.

  • Point72 Asset Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Point72 Asset Management sold 82,993 Sio Gene Therapies Inc. Common Stock shares in Q1 2018, an estimated $3.5M.
  • Point72 Asset Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2015 and held it in 5 quarters.
  • Point72 Asset Management's Sio Gene Therapies Inc. Common Stock position peaked at $9.03M in Q3 2016.
  • 81 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2018.

Based on Point72 Asset Management's 13F filing for Q1 2018, filed 15 May 2018.